Allotransplantation

MIMEDX to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Investor, GLOBE, Good tissue practice, Engineering, Patient, Tissue, Sterilization, Allotransplantation

MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced that senior management will present at the following investor conferences:

Key Points: 
  • MARIETTA, Ga., Nov. 10, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced that senior management will present at the following investor conferences:
    Institutional investors interested in meeting with senior management may contact their respective Canaccord Genuity or Piper Sandler representative.
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform

Retrieved on: 
Monday, November 7, 2022
Company, Lymphatic system, Private Securities Litigation Reform Act, Baylor College of Medicine, TT11, Hodgkin lymphoma, Center for Cell and Gene Therapy, Cell, Infrastructure as code, GLOBE, PRIME, European Medicines Agency, Graft-versus-host disease, FDA, Baylor University, Hematological Cancer Research Investment and Education Act, Neoplasm, Allotransplantation, Therapy, Trial of the century, Marketing, Epstein–Barr virus, Gene therapy, Cancer, Risk, GVHD, Technology, Center, Patient, Pharmaceutical industry

SINGAPORE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform developed jointly by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine. Tessa is currently advancing a pipeline of products that utilize CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.

Key Points: 
  • CD30.ALLO Virus specific T-cells (VSTs) are highly specialized T cells that can recognize CD30+ tumors.
  • During the development of the allogeneic technology platform, Tessa and Baylor College of Medicine had an exclusive option agreement for commercial rights to the technology.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022

Retrieved on: 
Thursday, November 3, 2022
Patient, LD, NEW, Company, Neoplasm, Private Securities Litigation Reform Act, MM, Vrije Universiteit Amsterdam, Alemtuzumab, 2021 Essex County Council election, PM, Society, Acute leukemia, U.S. Securities and Exchange Commission, CD52, Cyclophosphamide, GLOBE, CAR, FC, Population, Adult, TRAC, ASH, Degenerative disease, Relapse, Allotransplantation, Acute myeloid leukemia, Graft-versus-host disease, Nasdaq, Investigational New Drug, YouTube, Annual report, Social media, Clinical trial, Euronext Growth, Hodgkin lymphoma, Multiple myeloma, FCA, Forward-looking statement, Risk, NASDAQ, Immune system, Disease, Gene editing, Technology, Securities & Exchange Commission of Pakistan, AML, Time, UCART123, Cancer, Department, Pharmaceutical industry, Vaccine, Cellectis, Hematology

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the release of two abstracts, which were accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting taking place from December 10 to 13, 2022.

Key Points: 
  • The Company will present, in an oral session on December 12, preliminary clinical data from its AMELI-01 clinical trial (evaluating UCART123) in patients with relapsed/refractory acute myeloid leukemia (r/r AML).
  • Amsterdam University Medical Center (location VUmc), in collaboration with Cellectis, will also present, in a poster session on December 10, preclinical data supporting anti-tumor activity for Cellectis UCARTCS1 product candidate, which is being evaluated in clinical trial, MELANI-01, for patients with relapsed/refractory multiple myeloma (r/r MM).
  • Cellectis is excited to share preliminary clinical data from our AMELI-01 clinical trial, evaluating UCART123 in patients with relapsed and/or refractory acute myeloid leukemia.
  • The potential impact of previous therapy and tumor characteristics on the in vitro efficacy of UCARTCS1 was also investigated.

Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Patient, RNA, Lymphatic system, DNA, Private Securities Litigation Reform Act, Research, Society, University of California, Risk, GLOBE, CAR, Safety, Reindeer, Poster, ASH, Allotransplantation, University, Division, Nasdaq, Phenotype, PD-1, Annual report, U.S. Securities and Exchange Commission, Clinical trial, Genome, Rachel Haurwitz, Technology, Security (finance), CRISPR, Multicenter Automatic Defibrillator Implantation Trial, University of California, Irvine Medical Center, Next, CRISPR/Cpf1, Efficiency, Pharmaceutical industry, Vaccine, Sewing

The poster will provide details on the ANTLER clinical trial design and objectives.

Key Points: 
  • The poster will provide details on the ANTLER clinical trial design and objectives.
  • Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
  • Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Wugen to Present Data on WU-NK-101 for Relapsed / Refractory Acute Myelogenous Leukemia at The American Society of Hematology’s (ASH) 64th Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Research, Finance, Clinical Trials, Professional Services, Biotechnology, General Health, Health, Science, Oncology, Other Science, Bone marrow, Society, Cell, Acute leukemia, NK, TME, ASH, Allotransplantation, Phenotype, CIML, Natural killer T cell, AML, Immunotherapy, Patient, Cancer, Medical imaging, Fine chemical, Vaccine

The data will be presented at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10 13, 2022 in New Orleans, Louisiana.

Key Points: 
  • The data will be presented at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10 13, 2022 in New Orleans, Louisiana.
  • Together, these data demonstrate WU-NK-101 may represent an effective treatment modality for R/R AML.
  • Wugen is applying its proprietary Moneta platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer.
  • WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.

CareDx Demonstrates Power of AlloSure and Digital Health Transplant Solutions at American Society of Nephrology Kidney Week

Retrieved on: 
Wednesday, November 2, 2022
Health, Surgery, Genetics, Clinical Trials, Research, Science, Biotechnology, MPH, Annual report, DNA, Allotransplantation, CEO, Health, SEC, Time, Kidney International, Society, Nasdaq, American Society of Nephrology, ASN, Transplant, Associate, Patient, Precision medicine, 2021 Essex County Council election, De novo, Solution, Caregiver, Pharmaceutical industry, Dentistry, MD, Nephrology, Kidney

At ASN Kidney Week, CareDx is featured in nine abstracts and posters, and one oral presentation, several of which add to the clinical utility data showing AlloSure as an important surveillance tool for transplant patient management. These latest presentations are consistent with the findings of the landmark 2021 ADMIRAL study1 -- the industry’s first long-term, 3-year, multicenter prospective clinical validation for routine kidney transplant surveillance. The study showed that AlloSure provides an early and accurate assessment of allograft injury when used in routine kidney transplant surveillance and can predict long-term graft survival outcomes. AlloSureis the first donor-derived cell-free DNA (dd-cfDNA) solution to demonstrate clinical utility in prediction of de novo donor-specific antibody, and both subclinical and clinical rejection in a long-term study.1

Key Points: 
  • ASN Kidney Week is an excellent opportunity for CareDx to expand further into transplant nephrology in the community setting, where we will be sharing the latest AlloSure Kidney data and digital solutions to help nephrologists manage the complexities of transplant patient care, said Reg Seeto, CEO and President of CareDx.
  • At ASN Kidney Week, CareDx is featured in nine abstracts and posters, and one oral presentation, several of which add to the clinical utility data showing AlloSure as an important surveillance tool for transplant patient management.
  • CareDx is a provider of digital health solutions that powerfully link participating transplant centers, healthcare providers, and patients in better navigating the complex transplant journey to improve patient care.
  • During ASN Kidney Week CareDx will be onsite to highlight how its digital health solutions support clinical practice and help centers achieve operational efficiency.

BioStem Promotes Michael Fortunato, CPA to Chief Financial Officer

Retrieved on: 
Wednesday, October 26, 2022
SEC, Company, Accounting, Private Securities Litigation Reform Act, Forward-looking statement, Rutgers University, Controller, IPO, Physician, CPA, Technology, Allotransplantation, Compliance, Regenerative medicine, Public sector banks in India, American Association of Tissue Banks, OTC, American Association, Research, COVID-19, GLOBE, Association, FDA, San Francisco Bay Area, AATB, Health, Security (finance)

Mr. Fortunato brings over 28 years of expert level financial accounting, SEC reporting, M&A and IPO experience to BioStem.

Key Points: 
  • Mr. Fortunato brings over 28 years of expert level financial accounting, SEC reporting, M&A and IPO experience to BioStem.
  • BioStem has made substantial progress and is now reaching an exciting inflection point given our strong commercial momentum, said Jason Matuszewski, Chief Executive Officer of BioStem.
  • Looking at the future of BioStem, having Michael in the role of Chief Financial Officer will help bring the company to the next level given his extensive experience in finance, accounting, and strategic execution.
  • Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.

Bone Biologics CEO Issues Letter to Stockholders

Retrieved on: 
Tuesday, October 25, 2022
General Health, Health, Surgery, Other Health, Sheep, Spinal stenosis, Caregiver, Cell bank, Technology, Deformity, NB1, Bharat Immunologicals and Biologicals Corporation, Review, B cell, Technology transfer, CGMP, NASDAQ, Patient, Osteoporosis, Spondylolisthesis, Allotransplantation, Oswestry Disability Index, Degenerative disc disease, UCLA, Publication, Trial of the century, Spinal fusion, CDMO, Trauma, Safety, Letter, DBM, Clinical trial, Environment, Gold standard, MTF, Human, Vaccine, Pharmaceutical industry, Fine chemical, Medical device

Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.

Key Points: 
  • Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.
  • This potential lies in its ability to provide rapid, specific and guided control over bone regeneration.
  • This is the market Bone Biologics intends to address.
  • We believe our effort will be well-rewarded not only by patients, but also by caregivers and Bone Biologics stockholders.

Carbon's Developmental Bioabsorbable Elastomer Platform has Demonstrated Biocompatibility in Vivo

Retrieved on: 
Wednesday, October 26, 2022
LinkedIn, CA, Porosity, Bleeding, Leakage, Peripheral nervous system, 3D, Allotransplantation, Twitter, Tissue, Multimedia, Technology, SVP, Elasticity, Motion, Absorption, Deformity, Injury, Neuro, Solution, View, Silk, 3D printing, Facebook

REDWOOD CITY, Calif., Oct. 26, 2022 /PRNewswire/ -- Carbon, a leading 3D printing technology company, today announced that its developmental bioabsorbable elastomer platform has demonstrated biocompatibility in vivo, with all samples being designated as non-toxic and exhibiting tunable times for full absorption. This latest milestone indicates the elastomer's potential future development in biomedical lattice applications such as soft tissue repair, wound dressings, and nerve conduits.

Key Points: 
  • Carbon's developmental bioabsorbable elastomer offers impressive mechanical performance, biocompatibility, and tunability.
  • Additionally, current in vivo studies have demonstrated the required tissue tolerance and desirable healing responses for an implantable device through 26 weeks.
  • "We're very pleased to announce that Carbon's developmental bioabsorbable elastomer platform has demonstrated biocompatibility in vivo," said Jason Rolland, SVP of Materials at Carbon.
  • Carbon's bioabsorbable elastomer potentially could improve existing solutions by enhancing flexibility, porosity, neuro inductivity and neuro conductivity.

MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2

Retrieved on: 
Wednesday, October 19, 2022
Good tissue practice, Sterilization, Patient, Allotransplantation, Webcast, Tissue, Engineering, Online shopping, Medical imaging

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.

Key Points: 
  • MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare.
  • We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION process.
  • We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts.
  • MIMEDX has supplied over two million allografts, through both direct and consignment shipments.